0001493152-20-022048.txt : 20201223 0001493152-20-022048.hdr.sgml : 20201223 20201119182449 ACCESSION NUMBER: 0001493152-20-022048 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20201119 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LIXTE BIOTECHNOLOGY HOLDINGS, INC. CENTRAL INDEX KEY: 0001335105 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 202903526 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 248 ROUTE 25A STREET 2: NO. 2 CITY: EAST SETAUKET STATE: NY ZIP: 11733 BUSINESS PHONE: 310 203 2902 MAIL ADDRESS: STREET 1: 248 ROUTE 25A STREET 2: NO. 2 CITY: EAST SETAUKET STATE: NY ZIP: 11733 FORMER COMPANY: FORMER CONFORMED NAME: SRKP 7 INC DATE OF NAME CHANGE: 20050803 CORRESP 1 filename1.htm

LIXTE BIOTECHNOLGY HOLDINGS, INC.

248 Route 25A, No.2

East Setauket, NY 11733

November 19.2020

VIA EDGAR

Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549-6010

	Re:	Lixte Biotechnology Holdings, Inc.
		Registration Statement on Form S-1 (Reg. No. 333-248588)

Ladies and Gentlemen:

On behalf of Lixte Biotechnology Holdings, Inc., the undersigned hereby (a) withdraws the previous request that the above referenced Registration Statement be declared effective on Thursday November 19, 2020 and (b) requests that the Securities and Exchange Commission issue an order declaring the Registration Statement effective at 4:00 P.M., Washington, D.C. time, on Monday November 23,2020 or as soon thereafter as is practicable. This will confirm that no securities have been sold pursuant to the Registration Statement. Please call our counsel, David Ficksman, at 310-789-1290 to inform him of the effectiveness.

	Very truly yours,

	/s/ John Kovach
	John Kovach
	President and Chief Executive Officer